For Forest Labs, One Key To Life After Lexapro May Lie In The COPD Market
This article was originally published in The Pink Sheet Daily
Executive Summary
In their first-ever R&D day for investors, execs discussed pipeline candidates that are intended to guide the firm through the Lexapro patent expiration.